The global market for central venous catheters reached $3 billion in 2021 and is projected to grow at a CAGR of 6.3% during the forecast period of 2023 to 2030. A central venous catheter may also be referred to as a central line or a central venous line. It is a flexible tube that is put into the vein on the right side of the collarbone and led to the superior vena cava, a major vein that leads to the heart. A central venous catheter is used to administer various fluids, which are thus easily administered into the patients' bodies. The fluids consist of intravenous fluids, blood transfusions, and chemotherapy medications. These devices have proved life-saving for individuals who are unable to consume food orally. Consequently, the increasing prevalence of cardiovascular illness and chronic kidney disease, as well as the growing requirement for prolonged intravenous therapy in critically ill patients, will continue to drive demand for venous catheters over the forecast period. According to a research report published in Kidney International Reports in 2021, around 80% of patients with end-stage renal illness initiate kidney replacement therapy with a hemodialysis-central venous catheter (HD-CVC) in the U.S. A high frequency of chronic diseases results in increased patient traffic in medical and healthcare facilities. During the forecast period, the market for central venous catheters is anticipated to expand at a stable rate due to the high prevalence of chronic diseases such as cardiovascular diseases and chronic renal diseases, as well as a large elderly population sensitive to age-related ailments.
Product Innovation and Utilisation of Advanced Medical Technologies Will Stimulate Expansion
In response to the increasing demand for various types of central venous catheter devices, manufacturers are investing in R&D to produce more effective and superior products. This is expected to increase growth over the projection period. Similarly, the rising acceptance of innovative technologies during medical procedures and the implantation of medical devices casts a new light on the market for central venous catheters. It has been demonstrated that ultrasound-guided insertions increase the safety and efficacy of CVC placement and reduce the incidence of problems. Greater accessibility to product-based solutions, such as quality control and infection prevention recommendations, has boosted the worldwide central venous catheter market's total revenue growth. These aspects are largely influenced by the worldwide disease load, increased disposable income, and growing knowledge of the adoption of surgical techniques for disease management.
Rise of CVDs Fuelling Market Growth
The escalating prevalence of CVDs/cardiovascular disorders (coronary artery disease, atherosclerosis, cardiomyopathy, myocardial infarction, etc.) is one of the key drivers propelling the market's expansion from 2020 to 2030. In 2017, according to the American Heart Association (AHA), CVDs caused 868,662 deaths. CHD (coronary heart disease) was the leading cause of mortality in the United States in 2018 (42.1%), followed by stroke (17.0%), high BP (11.0%), Cardiac failure (9.6%), arterial disorders (2.8%), and other CVDs (17.0%). Due to the increase in CVDs, the usage of CVCs such as percutaneous central venous catheters, subclavian vein catheters, femoral venous catheters, non-tunneled percutaneous central venous catheters, triple lumen central venous catheters, subclavian central venous catheters, PICC line catheters, internal jugular vein catheters for dialysis, implanted ports, etc., as well as procedures. Additionally, the growing need for antimicrobial catheters, quick technical improvements, and the increase in the geriatric population are considerably driving the market's expansion as a whole. According to UNESA (Department of Economic and Social Affairs of the United Nations), there were roughly 727Mn persons aged 65 or over in the globe in 2020. By 2050, the number is projected to exceed 1.5 billion.
An Increase in The Number of CLABSI Patients Is Boosting Sales in China
The market for central venous catheters in China is primarily driven by the country's high incidence of central-line associated bloodstream infections (CLABSI). According to a multi-centre prospective study on CLABSI in ICUs of China in 2021, the incidence of CLABSI in ICUs of China is approximately 1.5/1000 catheter days. This high prevalence encourages the adoption of central venous catheters in the country, hence driving the market's expansion as a whole. Similarly, the simple availability of catheters at significantly reduced prices, favourable government backing, and the rising number of medical procedures conducted in the country would stimulate the expansion of the market for central venous catheters.
Market Demand for Non-Tunnelled Catheters Will Remain Strong
According to FMI, the CVC catheter segment presently dominates the global market for central venous catheters, and this trend is anticipated to continue throughout the projected period. Non-tunneled CVC catheters are the most popular among end users and account for approximately 77.0% of the global market. This is due to the increasing use of non-tunneled catheters in short-term therapy and emergencies. Since non-tunneled catheters are associated with lower treatment costs and shorter hospital stays, this sector has a significant impact on the overall growth of the central venous catheter market.
Key Factors Restraining the Central Venous Catheters Market
Several strategies for controlling and avoiding infections associated with intravascular catheters (CRI). However, CRIs continues to be one of the leading causes of hospital-acquired infections and are associated with longer hospital stays, higher medical costs, and mortality. It has been demonstrated that developing nations have significantly higher rates of device-associated infections, particularly those involving CVCs. Catheters, such as multi-lumen catheters, cannot be used to feed invasive devices, such as pacemakers or pulmonary artery catheters. In addition, a large number of product recalls have hindered the market's expansion as a whole. Cook Medical launched a voluntary recall on 360 batches of single-lumen CVCs, pressure monitoring sets, and trays on January 6, 2016, due to the possibility of catheter tip breakage and separation. The global recall involved a total of 17,827 devices.
Non-Antimicrobial Segment Dominated the Market by Property
In 2021, the non-antimicrobial catheter category held a market share of around 75% and is anticipated to maintain its leading position throughout the assessment period. This can be related to the growing preference among consumers for non-antimicrobial catheters because of their low price. Globally, non-coated or non-antimicrobial central venous catheters are widely distributed. The preference adjustments toward coated or anti-microbial catheters have not significantly reduced the incidence of CLABSI or other related illnesses. Therefore, from a production standpoint, non-anti-microbial catheters are mass-produced with minimal or no additional coating costs.
Double Lumens Catheters Dominated the Market by Design
In 2021, the double-lumen catheters category accounted for approximately 65% of the global central venous catheter market. Medium- and long-term use is better suited for chronic double-lumen or double-catheter insertions. With a growing number of hospital and ICU admissions, the category applies to patients receiving long-term care therapy, hence supporting a greater global market share.
The hospital Segment Dominated the End User Segment
The hospital's segment of the central venous catheter market held a revenue share of approximately 60% in 2021 and is expected to increase at a faster rate during the forecast period. This can be due to the increasing prevalence of chronic diseases and age-related conditions, the availability of modern medical equipment for patients requiring intensive care, and the rapid expansion of hospitals worldwide.
U.S. to Lead the Global Market
The global market for central venous catheters is classified by region into North America, Latin America, Europe, Asia-Pacific, the Middle East, and Africa. The availability of reimbursement for central venous catheters is anticipated to propel the expansion of the North American central venous catheter market during the forecast period. The U.S. will continue to dominate the worldwide central venous catheters market throughout the forecast, accounting for approximately 40% of the market in 2021. The expansion of the U.S. market for central venous catheters is fuelled by the increasing prevalence of chronic diseases, the high adoption of central venous catheter insertions, and the strong presence of some of the world's major medical device manufacturers. In the United States, chronic diseases such as cancer and heart disease have risen sharply over time. According to the Centres for Condition Control and Prevention (CDC), 6 out of 10 U.S. individuals have a chronic disease. In turn, this will increase the need for medical equipment such as central venous catheters. In addition, the U.S. market for central venous catheters is expected to grow at a CAGR of 5.8% during the forecast period of 2023 to 2030, owing to the presence of an established healthcare infrastructure and insurance and reimbursement policies for conventional medical operations. In 2021, Germany held a 3% share of the global central venous catheter market, which is expected to expand at a steady rate during the forecast period due to the presence of frequently revised standard guidelines for central venous access, booming medical tourism, an increase in hospital stays due to the growing prevalence of chronic diseases, and technological advancements in catheters. Germany's sales of central venous catheters are bolstered by innovations in healthcare and practice that approach a standard model of the care continuum. Similarly, the rapid expansion of the nation's healthcare infrastructure is anticipated to offer possibilities for manufacturers of central venous catheters.
Product Innovation Remains the Key Industry Strategy
Key companies are continuously focused on enhancing their product portfolios by introducing new, innovative products. In addition, they are considering implementing strategies such as partnerships, mergers, acquisitions, and collaborations to increase their revenue share and global footprint. Key competitors in this market include B. Braun Melsungen AG, Becton, Dickinson and Company, ICU Medical, Inc., Poly Medicure Ltd., Teleflex Incorporated, Lepu Medical Technology Co., Ltd., Cook Group, Insung Medical, VOGT Medical, ZOLL Medical Corporation, EETA Surgical, QMD, and Kimal. In 2021, Teleflex, Becton Dickinson, and Cook Medical had the majority of the global CVC market share. Teleflex was the foremost competitor in the global Central Venous Catheter market. Beckton Dickinson (BD) was the second and Cook Medical was ranked as the third largest competitor.
Historical & Forecast Period
This study report represents analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Central Venous Catheters market are as follows:
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.
| ATTRIBUTE | DETAILS |
|---|---|
| Research Period | 2022-2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Year | 2022 |
| Unit | USD Million |
| Segmentation | |
Object
| |
Real Estate
| |
Design
| |
End User
| |
|
Region Segment (2022-2032; US$ Million)
|
Key questions answered in this report
